Présentation
The overall aim of the project is to investigate the immune responses to HBV and develop novel treatment concepts to cure chronic HBV. HBV is a major global health problem with over 257 million people chronically infected and over 887,000 deaths per year. A combination of direct acting antivirals and immunomodulatory treatments is considered key to achieving HBV cure. Strategies with finite duration of treatment would certainly improve the management of patients and prevention of HBV associated liver diseases.
